Risk-Adapted Combined-Modality Therapy in Early-Stage Extranodal Natural Killer-/T-Cell Lymphoma: A Markov Model–Based Cost-Effectiveness Analysis

PURPOSECombined-modality therapy (CMT) improves survival in patients with early-stage extranodal natural killer-/T-cell lymphoma (ENKTCL) compared with radiotherapy (RT) alone. However, the effect is inadequate for low-risk patients as defined by nomogram-revised risk index (NRI). As such, it remain...

Fuld beskrivelse

Bibliografiske detaljer

Principais autores:	Jing Yang, Qiu-Zi Zhong, Li-Ting Qian, Yong Yang, Xiao-Rong Hou, Xue-Ying Qiao, Hua Wang, Yuan Zhu, Jian-Zhong Cao, Jun-Xin Wu, Tao Wu, Su-Yu Zhu, Mei Shi, Hui-Lai Zhang, Xi-Mei Zhang, Hang Su, Yu-Qin Song, Jun Zhu, Yu-Jing Zhang, Hui-Qiang Huang, Ying Wang, Xia He, Li-Ling Zhang, Shu-Lian Wang, Shu-Nan Qi, Bao-Lin Qu, Ye-Xiong Li
Format:	Artigo
Sprog:	Inglês
Udgivet:	American Society of Clinical Oncology 2026-01-01
Serier:	JCO Global Oncology
Online adgang:	https://ascopubs.org/doi/10.1200/GO-24-00435
Tags:	Tilføj Tag Ingen Tags, Vær først til at tagge denne postø!